TRex Bio, Inc.

Based in the US, TRex Bio, Inc. operates as a biotechnology company focused on developing therapeutics for immune-mediated diseases through advanced human tissue analysis. Founded in 2018 and headquartered in San Francisco, US, TRex Bio, Inc. specializes in innovative therapeutics targeting immune-mediated diseases.

TRex Bio specializes in the development of innovative therapeutics for immune-mediated diseases through its proprietary human tissue-based Deep Biology Platform. This platform enables the company to analyze T regulatory (T reg) cell behavior within human tissues, linking dysregulation to various diseases. By utilizing advanced sequencing and computational tools alongside human assay systems, TRex Bio aims to identify and create therapeutics that can restore tissue homeostasis and mitigate inflammatory processes. The company’s scientific focus centers on harnessing a vast collection of human tissue samples, gathered from both healthy and diseased states, to inform their drug discovery pipeline.

Its primary customers include pharmaceutical companies and research institutions seeking to enhance their understanding of immune response mechanisms and develop targeted immunotherapies, with a market presence primarily in North America and Europe. TRex Bio's revenue model is structured around partnerships and collaborations with pharmaceutical companies, as well as potential licensing agreements for its therapeutic candidates. Transactions typically involve collaborative research and development agreements, where clients invest in the development of specific therapeutics tailored to immune-mediated diseases. These partnerships allow for shared resources and expertise in the drug discovery process.

The company’s flagship products, including TRB-051 and TRB-061, are positioned as breakthrough candidates in the immunology space, attracting significant interest from collaborators and investors alike. Revenue is generated through direct funding from strategic partnerships, research grants, and potential royalties from product sales upon successful commercialization of their therapeutics. In January 2026, TRex Bio, Inc. raised USD 50 million in venture funding from Janus Henderson Investors, Balyasny Asset Management L.

P. , Affinity Asset Advisors, Alexandria Venture Investments, Avego, Delos Capital, Eli Lilly & Company, Johnson & Johnson Innovation, Pfizer Venture Investments, Polaris Partners, and SV Health Investors. The company will use the funding to continue clinical work on its lead program and move its two early‑stage programs toward initial human trials for inflammatory and autoimmune diseases.